Last updated 2026-07-20
- Raised $28.5M Series C led by Biotel, Feb 2021
- Raised $12M Series D led by Cystic Fibrosis Foundation, Mar 2024
- Raised $1M Series A led by Integra Holdings, Oct 2018
Total raised
$41.5M
Last: B Round 2021-05
Stage
Series B
Founded
2017
Headcount
13
HQ
Jerusalem, Israel
Sector
Health Tech & Life Sciences
About
SpliSense is an Israeli clinical-stage biotechnology company focused on developing transformative RNA-based treatments for unmet needs relating to cystic fibrosis (CF) and other genetic pulmonary illnesses. The company's pioneering platform harnesses Antisense Oligonucleotides (ASOs) to target the root cause of diseases by overcoming specific genetic mutations and modulating protein expression and function. Their technology is based on the research of Prof. Batsheva Kerem from the Hebrew University. SpliSense's pipeline includes innovative therapies in various stages, from discovery to clinical phase, with a lead inhaled ASO therapy, SPL84, for cystic fibrosis. The company has robust, diverse IP protecting its technologies and programs.
Funding history · 4 rounds · $41.5M total
2024-03
D Round
$12.0M
★ Cystic Fibrosis FoundationOrbiMedIntegra Holdings
2021-02
C Round
$28.5M
★ Biotel★ OrbiMed★ Integra Holdings★ Israel Biotech Fund★ Cystic Fibrosis Foundation
2020-01
B Round
Undisclosed
★ Israel Biotech Fund
2018-10
A Round
$1.0M
★ Integra Holdings
Headcount over time
From 5 (2020-10) to 16 (2025-12) · +11 (+220%) · 17 points · source: Finder history + radar grounding
Q&A
- What is SpliSense's primary focus?
- SpliSense is a clinical-stage biopharmaceutical company that develops transformative RNA-based treatments for pulmonary diseases, specifically using Antisense Oligonucleotides (ASOs).
- What is SpliSense's lead product candidate and its current development stage?
- SpliSense's lead candidate is SPL84, an inhaled ASO therapy for cystic fibrosis patients with the 3849+10kb C→T mutation. It is currently in Phase 2b clinical trials.
- Which investors participated in SpliSense's Series B funding round?
- In May 2021, SpliSense raised a Series B round with participation from OrbiMed and Cystic Fibrosis Foundation.
- Has SpliSense received any recent grants?
- Yes, SpliSense received a grant of $8,500,000 from the Cystic Fibrosis Foundation in April 2024, and is projected to receive another grant of $13,000,000 from the same foundation in June 2026.
- What was the most recent regulatory designation SpliSense received for SPL84?
- In May 2024, SpliSense received FDA Fast Track Designation for SPL84 for the treatment of cystic fibrosis.
- What was the outcome of SpliSense's Phase 2 study for SPL84?
- In September 2025, SpliSense reported positive results from its Phase 2 study of SPL84 in cystic fibrosis.
- What is the employee count for SpliSense?
- SpliSense has 11-50 employees.
- What is the total amount of funding SpliSense has raised to date?
- SpliSense has raised a total of $43,000,000 USD.
Team · 7
Batsheva Kerem
Founder · Scientific Founder
CBO
Asaf Cohen
VP CMC
Chairman
Sectors & technology
Primary sector
Health Tech & Life Sciences
Technologies
Target customers
Business model
B2B
Highlights
Patents
Tags
medical-technologiespharma-companiespharmaceuticalsbiotechnologydrug-developmenttreatmentsgeneticsrna-based-therapiesantisense-oligonucleotidescystic-fibrosispulmonary-diseases
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | splisense.com/ |
|---|---|
| linkedin.com/company/77849119 |
Identifiers & details
| Founded | 2017 |
|---|---|
| Employees (exact) | 13 |
Radar intelligence
Patents
| EPO | 9 |
|---|
Publications (Crossref)
| Works | 3 |
|---|
Web history (Wayback)
| Domain | splisense.com |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|